← Back to Search

Lymph Node Sampling for Lung Cancer

N/A
Recruiting
Led By Inderdeep Dhaliwal, MD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

This trial will compare two methods of cancer treatment to see which is more effective in patients with non-small cell lung cancer.

Who is the study for?
This trial is for adults over 18 with Non-Small Cell Lung Cancer (NSCLC) who have undergone recent staging investigations. It's aimed at those with a good performance status, up to 5 metastases, and plans for radical treatment of all cancer sites. Pregnant women, individuals unable to consent, or those with contraindications to EBUS/EUS or chest radiotherapy cannot participate.Check my eligibility
What is being tested?
The study tests if sampling lymph nodes using EBUS-TFNA or EUS-FNA can better determine the extent of nodal disease in NSCLC compared to imaging alone. Participants will also receive Stereotactic Ablative Radiotherapy (SABR), a precise high-dose radiation therapy.See study design
What are the potential side effects?
Potential side effects from the procedures may include discomfort at the biopsy site, bleeding, infection risk from needle aspiration and general risks associated with anesthesia. SABR may cause skin irritation, fatigue, shortness of breath and other localized symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes to treatment intent and/or plan
Secondary outcome measures
Determine the proportion of patients with complications of endoscopic procedure
Determine the proportion of patients with occult mediastinal metastasis
Determine the sensitivity and specificity of radiologic staging of hilar/mediastinal lymph nodes
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment2 Interventions
Small pieces of suspicious chest lymph nodes will be removed with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Non-Small Cell Lung Cancer (NSCLC) include targeted therapies, chemotherapy, and radiation therapy. Targeted therapies inhibit specific molecular pathways, such as EGFR or ALK mutations, that drive cancer growth. Chemotherapy works by killing rapidly dividing cells, including cancer cells, through interference with cell division. Radiation therapy uses high-energy rays to destroy cancer cells by damaging their DNA. Accurate lymph node sampling using EBUS-TFNA or EUS-FNA is essential for precise staging and molecular diagnosis, which helps in selecting the most effective targeted therapies and treatment plans for NSCLC patients.
Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
666 Previous Clinical Trials
414,237 Total Patients Enrolled
Academic Medical Organization of Southwestern OntarioOTHER
14 Previous Clinical Trials
1,334 Total Patients Enrolled
Inderdeep Dhaliwal, MDPrincipal InvestigatorLondon Health Sciences Centre, Lawson Health Research Institute
~7 spots leftby May 2025